Clinical application of the adenosine triphosphate-based response assay in intravesical chemotherapy for superficial bladder cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 2, 2012, Pages 689-692

  Ge, Wen Qing ^a   Pu, Jin Xian ^a   Zheng, Shi Ying ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Adenosine triphosphate; Chemotherapy response assay; Superficial bladder cancer

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT;

ARTICLE; BLADDER TUMOR; CANCER GRADING; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR RECURRENCE;

ADENOSINE TRIPHOSPHATE; ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 84866462302     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.2.689     Document Type: Article

References (20)

1. Cree IA, Andreotti PE (1997). Measurement of cytotoxicity by ATP based luminescence assay in primary cell cultures and cell lines. Toxicol In Vitro, 11, 553-6.
2. Cree IA, Kurbacher CM (1997). Individualizing chemotherapy for solid tumors-is there any alternative? Anticancer Drugs, 8, 541-8.
3. Cree IA, Kurbacher CM, Lamont A, et al (2007). A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs, 18, 1093-101.
4. Ekwall B, Sussman N (2000). ATP is the most accurate endpoint for in vitro predicting of cytotoxicity. ATLA, 28, 201-34.
5. Garcia O, Massieu L (2003). Glutamate uptake inhibitor L-Transpyrrolidine 2, 4-dicarboxylate becomes neurotoxic in the presence of subthreshold concentrations of mitochondrial toxin 3-nitropropionate: involvement of mitochondrial reducing activity and ATP production. J Neurosci Res, 74, 956-66.
6. Gasión JP, Cruz JF (2006). Improving Efficacy of Intravesical Chemotherapy. European Urology, 50, 225-34.
7. Huh JW, Park YA, Lee KY, et al (2009). Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer-secondary publication. Yonsei Med, 50, 697-703.
8. Jichlinski P, Guillou L, Karlsen SJ, et al (2003). Hexylaminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer-A multicenter study. J Urol, 170, 226-9.
9. Kangas L, Gronroos M, Nieminen AL (1984). Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med Biol, 62, 338-43.
10. Kornmann M, Beger HG, Link KH (2003). Chemosensitivity testing and test-directed chemotherapy in human pancreatic cancer. Recent Results Cancer Res, 161, 180-95.
11. Kurbacher CM, Grecu OM, Stier U, et al (2003). ATP chemosensitivity testing in ovarian and breast cancer:early clinical trials. Recent Results Cancer Res, 161, 221-30.
12. Moon YW, Choi SH, Kim YT, et al (2007). Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. Cancer, 109, 1829.
13. Mueller H, Kassack MU, Wiese M (2004). Comparison of the usefulness of the MTT, ATP and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines. J Biomol Screen, 9, 506-15.
14. O'Meara AT, Sevin BU (2001). Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. Gynecol Oncol, 83, 334-421.
15. Riedl CR, Daniltchenko D, Koenig F, et al (2001). Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrencen rate in superficial bladder cancer. J Urol, 165, 1121-3.
16. Schmittgen TD, Au JLS, Wientjes G, et al (1991). Cultured human bladder tumors for pharmacodynamic studies. Urology, 145, 203-7.
17. Serretta V, Galuffo A, Pavone C, et al (2005). Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. Urology, 65, 65-9.
18. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al (2006). Predicting recurrence and progression in individual patients with stage Ta T1bladder cancer using EORTC risk tables:a combined analysis of 2596 patients from seven EORTC trial. Eur Urol, 49, 466-77.
19. Ulukaya E, Ozdikicioglu F, Oral AY, et al (2008). The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested. Toxicol In Vitro, 22, 232-9.
20. Yamaue H, Tanimura H, Tsunoda T, et al (1991). Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay. Eur J Cancer, 27, 1258-63.